Drug | Name of study | No. of patients | RR% of vertebral Fx | RR% of hip Fx |
Antiresorptive therapies | ||||
Calcitonin | PROOF | 1,255 | 36 | NS |
Raloxifene | MORE | 7,704 | 30–55 | NS |
HRT/ERT | WHI | 16,608 | 34 | 34–39 |
Alendronate | FIT-1 | 2,027 | 47 | 51 |
Risedronate | VERT | 2,458 | 41–49 | NA |
Risedronate | HIP-OP | 5,445 | NA | 40 |
Ibandronate | BONE | 2,946 | 52 | NS |
Zoledronic acid | HORIZON | 7,765 | 70 | 41 |
Denosumab | FREEDOM | 7,868 | 68 | 40 |
Anabolic therapies | ||||
Teriparatide | NCT00670501* | 1,637 | 84 | NA |
Abaloparatide | ACTIVE | 2,463 | 86 | 43 (NV Fx) |
Romosozumab | FRAME | 7,180 | 83 | NS |
↵* ClinicalTrials.gov identifier.
RR = relative risk reduction; Fx = fracture; HRT/ERT = hormone replacement therapy/estrogen replacement therapy; NS = not significant; NA = not available; NV Fx = nonvertebral fracture.